These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 16409461

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
    Turpie AG, Fisher WD, Bauer KA, Kwong LM, Irwin MW, Kälebo P, Misselwitz F, Gent M, OdiXa-Knee Study Group.
    J Thromb Haemost; 2005 Nov; 3(11):2479-86. PubMed ID: 16241946
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group.
    N Engl J Med; 2008 Jun 26; 358(26):2765-75. PubMed ID: 18579811
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
    Sindali K, Rose B, Soueid H, Jeer P, Saran D, Shrivastava R.
    Eur J Orthop Surg Traumatol; 2013 May 26; 23(4):481-6. PubMed ID: 23412293
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
    Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, Spaeder J, Turpie AG.
    Thromb Haemost; 2010 Dec 26; 104(6):1150-7. PubMed ID: 20886185
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
    Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators.
    Lancet; 2008 Jul 05; 372(9632):31-9. PubMed ID: 18582928
    [Abstract] [Full Text] [Related]

  • 15. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
    Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI.
    Thromb Haemost; 2010 Sep 05; 104(3):642-9. PubMed ID: 20589317
    [Abstract] [Full Text] [Related]

  • 16. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
    Turpie AG, Gallus AS, Hoek JA, Pentasaccharide Investigators.
    N Engl J Med; 2001 Mar 01; 344(9):619-25. PubMed ID: 11228275
    [Abstract] [Full Text] [Related]

  • 17. SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study.
    Lassen MR, Dahl O, Mismetti P, Zielske D, Turpie AG.
    J Am Coll Cardiol; 2008 Apr 15; 51(15):1498-504. PubMed ID: 18402906
    [Abstract] [Full Text] [Related]

  • 18. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).
    Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Wetherill G, Wilpshaar JW, Meems L, ONYX-2 STUDY GROUP.
    J Thromb Haemost; 2010 Apr 15; 8(4):714-21. PubMed ID: 20088935
    [Abstract] [Full Text] [Related]

  • 19. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
    Van Thiel D, Kalodiki E, Wahi R, Litinas E, Haque W, Rao G.
    Clin Appl Thromb Hemost; 2009 Apr 15; 15(4):389-94. PubMed ID: 19608550
    [Abstract] [Full Text] [Related]

  • 20. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
    Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD, RECORD4 Investigators.
    Lancet; 2009 May 16; 373(9676):1673-80. PubMed ID: 19411100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.